CGEM
Cullinan Therapeutics, Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$22.09
−0.32%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.85
- Revenue estimate
- $2.0M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.81
- EPS estimate
- -$0.80
- Revenue actual
- —
- Revenue estimate
- $3.7M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 9
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +8.2%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Strong Buy
- Price target
- $37
- PT range
- $30 – $42
- Analysts
- 4
4 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026